Skip to content
Screener

Alumis Inc. ALMS Free cash flow margin

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
23.3%-7.3pp
Amgen logo
AmgenAMGN
26.7%-3.7pp
Immunome logo
ImmunomeIMNM
-5,118.9%-8,601pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-11,123.8%-13,374pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
17.7%+0.9pp
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-756.5%—

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×—

Profitability

See full
Operating margin-5,364%—
Net margin-2,825.7%—

Returns & leverage

See full
Return on equity-64.6%—
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

free cash flow/total revenue=-4,487.4%

Based on trailing twelve months.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s free cash flow margin?
Alumis Inc. (ALMS) reported free cash flow margin of -4,487.4% in Q1 2026.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Ask your AI about Alumis Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude